
    
      CD19+ B-ALL patients who have relapsed after murine-based CD19 CAR-T (CD19mCAR-T) treatment
      and/or have limited clinical response to CD19mCAR-T will be enrolled to receive CD19 hsCAR-T
      treatment.
    
  